DUBLIN, Oct 3 (Reuters) - U.S. biotechnology company Amgen Inc (AMGN.O) said on Wednesday it had shelved plans for a production plant in southern Ireland which would have generated 1,100 jobs. Amgen said the decision to postpone indefinitely the building of the factory in County Cork was “based purely on developments relating to Amgen’s global business” and was no reflection on Ireland.
In a statement, the company said it would keep the site on which the new plant -- intended mainly to supply the European market -- was to be built. Amgen, whose business has been affected by tighter regulatory restrictions on drugs, has embarked on a cost-cutting programme that includes reducing its global workforce by up to 14 percent.
Plans for the Cork facility were announced last year. It had been expected to be operational by 2012.
Drugs made by Amgen, which is headquartered in California, include Vectibix for cancer and arthritis treatment Enbrel.